PE20121394A1 - Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma - Google Patents
Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la mismaInfo
- Publication number
- PE20121394A1 PE20121394A1 PE2012000861A PE2012000861A PE20121394A1 PE 20121394 A1 PE20121394 A1 PE 20121394A1 PE 2012000861 A PE2012000861 A PE 2012000861A PE 2012000861 A PE2012000861 A PE 2012000861A PE 20121394 A1 PE20121394 A1 PE 20121394A1
- Authority
- PE
- Peru
- Prior art keywords
- tablet
- quinazoline
- weight
- amount
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 102000003678 AMPA Receptors Human genes 0.000 title 1
- 108090000078 AMPA Receptors Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Chemical group 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical group F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMULACION FARMACEUTICA BAJO LA FORMA DE TABLETA QUE COMPRENDE: HIDROXIPROPILCELULOSA EN UNA CANTIDAD DE ENTRE 2% Y 10% POR PESO DE LA TABLETA Y UN COMPUESTO ACTIVO DERIVADO DE 1H-QUINAZOLINA-2,4-DIONA DE FORMULA (I) EN UNA CANTIDAD DE ENTRE 5% Y 27,5% POR PESO DE LA TABLETA, DONDE R1 ES CF3, CHF2, CH2F, CH3CHF, ENTRE OTROS; R2 ES ALQUILO SUSTITUIDO POR HALOGENO, NITRO, CIANO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS DE FORMULA (I): (i), (ii), (iii), ENTRE OTROS. TAMBIEN PUEDE COMPRENDER UN RELLENO INSOLUBLE EN AGUA TAL COMO CELULOSA MICROCRISTALINA, EN UNA CANTIDAD DE 25% A 50% POR PESO DE LA TABLETA, UN DESINTEGRADOR TAL COMO GLICOLATO SODICO DE ALMIDON EN UNA CANTIDAD DE 2,5% A 15% POR PESO DE LA TABLETA, Y OTROS EXCIPIENTES TALES COMO UN AYUDANTE DE FLUJO Y UN LUBRICANTE. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS DE FORMULA (I) TIENEN ACTIVIDAD ANTAGONISTA DEL RECEPTOR AMPA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28898509P | 2009-12-22 | 2009-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121394A1 true PE20121394A1 (es) | 2012-10-29 |
Family
ID=43610748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000861A PE20121394A1 (es) | 2009-12-22 | 2010-12-21 | Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120263791A1 (es) |
| EP (1) | EP2515873A1 (es) |
| JP (1) | JP2013515076A (es) |
| KR (1) | KR20120105035A (es) |
| CN (2) | CN104013587A (es) |
| AU (1) | AU2010336510B2 (es) |
| BR (1) | BR112012016920A2 (es) |
| CA (1) | CA2784996A1 (es) |
| CL (1) | CL2012001689A1 (es) |
| EC (1) | ECSP12011994A (es) |
| GT (1) | GT201200209A (es) |
| MA (1) | MA33834B1 (es) |
| MX (1) | MX2012007320A (es) |
| NZ (1) | NZ600717A (es) |
| PE (1) | PE20121394A1 (es) |
| PH (1) | PH12012501289A1 (es) |
| RU (1) | RU2012131051A (es) |
| SG (1) | SG181787A1 (es) |
| WO (1) | WO2011079119A1 (es) |
| ZA (1) | ZA201204607B (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2465693A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
| SG10201809313WA (en) * | 2005-09-29 | 2018-11-29 | Novartis Ag | Formulation comprising metformin and vildagli ptin |
| WO2007106182A2 (en) * | 2005-11-09 | 2007-09-20 | Novartis Ag | Process for making pharmaceutical compositions with a transient plasticizer |
| JP5401327B2 (ja) * | 2008-02-11 | 2014-01-29 | 大日本住友製薬株式会社 | 溶出性の改善された錠剤 |
-
2010
- 2010-12-21 PE PE2012000861A patent/PE20121394A1/es not_active Application Discontinuation
- 2010-12-21 JP JP2012546151A patent/JP2013515076A/ja active Pending
- 2010-12-21 PH PH1/2012/501289A patent/PH12012501289A1/en unknown
- 2010-12-21 US US13/518,027 patent/US20120263791A1/en not_active Abandoned
- 2010-12-21 AU AU2010336510A patent/AU2010336510B2/en not_active Expired - Fee Related
- 2010-12-21 EP EP10803319A patent/EP2515873A1/en not_active Withdrawn
- 2010-12-21 NZ NZ600717A patent/NZ600717A/en not_active IP Right Cessation
- 2010-12-21 CN CN201310590709.7A patent/CN104013587A/zh active Pending
- 2010-12-21 KR KR1020127019189A patent/KR20120105035A/ko not_active Withdrawn
- 2010-12-21 RU RU2012131051/15A patent/RU2012131051A/ru not_active Application Discontinuation
- 2010-12-21 SG SG2012044905A patent/SG181787A1/en unknown
- 2010-12-21 CN CN2010800643985A patent/CN102770124A/zh active Pending
- 2010-12-21 BR BR112012016920A patent/BR112012016920A2/pt not_active IP Right Cessation
- 2010-12-21 WO PCT/US2010/061553 patent/WO2011079119A1/en not_active Ceased
- 2010-12-21 MX MX2012007320A patent/MX2012007320A/es not_active Application Discontinuation
- 2010-12-21 CA CA2784996A patent/CA2784996A1/en not_active Abandoned
-
2012
- 2012-06-18 MA MA34983A patent/MA33834B1/fr unknown
- 2012-06-21 CL CL2012001689A patent/CL2012001689A1/es unknown
- 2012-06-21 ZA ZA2012/04607A patent/ZA201204607B/en unknown
- 2012-06-21 EC ECSP12011994 patent/ECSP12011994A/es unknown
- 2012-06-22 GT GT201200209A patent/GT201200209A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012007320A (es) | 2012-07-20 |
| CN104013587A (zh) | 2014-09-03 |
| ZA201204607B (en) | 2013-02-27 |
| AU2010336510B2 (en) | 2014-06-26 |
| SG181787A1 (en) | 2012-07-30 |
| NZ600717A (en) | 2014-06-27 |
| AU2010336510A1 (en) | 2012-07-12 |
| KR20120105035A (ko) | 2012-09-24 |
| RU2012131051A (ru) | 2014-01-27 |
| MA33834B1 (fr) | 2012-12-03 |
| CA2784996A1 (en) | 2011-06-30 |
| EP2515873A1 (en) | 2012-10-31 |
| BR112012016920A2 (pt) | 2016-04-12 |
| WO2011079119A1 (en) | 2011-06-30 |
| PH12012501289A1 (en) | 2013-01-07 |
| JP2013515076A (ja) | 2013-05-02 |
| ECSP12011994A (es) | 2012-07-31 |
| US20120263791A1 (en) | 2012-10-18 |
| GT201200209A (es) | 2013-09-09 |
| CL2012001689A1 (es) | 2013-01-11 |
| CN102770124A (zh) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201391662A1 (ru) | Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2 | |
| EA201590873A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов | |
| CY1116328T1 (el) | Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης | |
| UA99132C2 (ru) | Производные дикарбоновых кислот как агонисты рецепторов s1p1 | |
| BRPI0809931B8 (pt) | antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo | |
| MX2012010966A (es) | Derivados de triazina disustituidos farmaceuticamente activos. | |
| MX2023001812A (es) | Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. | |
| JO3078B1 (ar) | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| PE20080094A1 (es) | COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO | |
| PE20121131A1 (es) | Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina | |
| MX2015013328A (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago. | |
| PH12017501424A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| BRPI0409809A (pt) | formulação farmacêutica do sal de sódio de telmisartano | |
| AU2014374259A1 (en) | Novel compositions | |
| NZ599762A (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
| PE20060768A1 (es) | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano | |
| AR071706A1 (es) | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. | |
| ES2847904T3 (es) | Medicamento para la prevención o el tratamiento de la hipertensión | |
| MX2009012933A (es) | Derivados de ariloxazol ariloxadiazol y bencimidazol como moduladores de la actividad del receptor de somatostatinas. | |
| MX2023006696A (es) | Composiciones farmaceuticas que comprenden un agonista cannabinoide. | |
| CN103655579A (zh) | 一种厄贝沙坦氢氯噻嗪药用复方组合物及其制备方法 | |
| RU2020115172A (ru) | Фармацевтическая композиция, содержащая хинолиновое производное | |
| RU2011145436A (ru) | Композиции с немедленным высвобождением лекарственного средства | |
| TWI455711B (zh) | 用以抑制前驅蝕骨細胞生長之醫藥組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |